Concepedia

First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study

Siow Ming Lee, Christian Schulz, Kumar Prabhash, Dariusz M. Kowalski, Aleksandra Szczęsna, Baohui Han, Achim Rittmeyer, Toby Talbot, David Vicente, Raffaele Califano,

The Lancet · 2023 · 158 citations · 19 references

DOI

Concepts

References

19

Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer

Joan H. Schiller, David Harrington, Chandra P. Belani et al. · New England Journal of Medicine · 2002 · 5K citations

, , +7

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Achim Rittmeyer, Fabrice Barlési, Daniel Waterkamp et al. · The Lancet · 2016 · 4.8K citations · Full text

, , +13

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

Louis Fehrenbacher, Alexander I. Spira, Marcus Ballinger et al. · The Lancet · 2016 · 2.8K citations

, , +12

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

David Planchard, Sanjay Popat, Keith M. Kerr et al. · Annals of Oncology · 2018 · 2.3K citations · Full text

, , +15

Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC

Roy S. Herbst, Giuseppe Giaccone, Filippo de Marinis et al. · New England Journal of Medicine · 2020 · 1.7K citations · Full text

, , +17